Immix Biopharma (IMMX) Free Cash Flow (2021 - 2026)
Immix Biopharma (IMMX) posted Free Cash Flow of -$9.9 million for Q1 2026, up 11.93% sequentially from -$11.2 million in Q4 2025, and down 462.49% YoY from $2.7 million in Q1 2025.
Immix Biopharma (IMMX) Free Cash Flow (2021 - 2026) Analysis & Trends
Immix Biopharma has reported Free Cash Flow for 6 years, with the latest figure at -$9.9 million in Q1 2026.
- Quarterly Free Cash Flow fell 462.49% year-over-year to -$9.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$32.8 million (down 144.61% YoY) and the FY2025 annual result came in at -$24.7 million, down 56.37% from the prior year.
- Free Cash Flow rose to -$9.9 million in Q1 2026 per IMMX's latest filing, from -$11.2 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$547066.0 in Q2 2022 and troughed at -$11.2 million in Q4 2025.
- A 5-year average of -$4.1 million and a median of -$3.5 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow slumped 2781.24% in 2022, then soared 57.55% in 2025.
- Over 5 years, Free Cash Flow stood at -$3.9 million in 2022, then soared by 31.08% to -$2.7 million in 2023, then increased by 26.29% to -$2.0 million in 2024, then tumbled by 464.44% to -$11.2 million in 2025, then rose by 11.93% to -$9.9 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$9.9 million, -$11.2 million, and -$6.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | -11.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.76 Mn |
| Jun 30, 2026 | -11.76 Mn |
| Mar 31, 2026 | -9.86 Mn |
| Mar 31, 2026 | -9.86 Mn |
| Dec 31, 2025 | -11.19 Mn |
| Dec 31, 2025 | -11.19 Mn |
| Sep 30, 2025 | -6.28 Mn |
| Sep 30, 2025 | -6.28 Mn |
| Jun 30, 2025 | -5.44 Mn |
| Jun 30, 2025 | -5.44 Mn |
| Mar 31, 2025 | -1.75 Mn |
| Mar 31, 2025 | -1.75 Mn |
| Dec 31, 2024 | -1.98 Mn |
| Dec 31, 2024 | -1.98 Mn |
| Sep 30, 2024 | -4.31 Mn |
| Sep 30, 2024 | -4.31 Mn |
| Jun 30, 2024 | -5.35 Mn |
| Jun 30, 2024 | -5.35 Mn |
| Mar 31, 2024 | -4.13 Mn |
| Mar 31, 2024 | -4.13 Mn |